High Lp(a): the silent cardiovascular risk factor

What Lp(a) is, and why genetics drive it

Lipoprotein(a), or Lp(a), is a lipoprotein particle structurally similar to LDL cholesterol but with an additional protein called apolipoprotein(a) attached. This structural difference makes Lp(a) more atherogenic than standard LDL: it promotes plaque formation in arterial walls, interferes with clot breakdown (fibrinolysis), and may accelerate calcification of the aortic valve. A 2022 JAMA Cardiology review established Lp(a) as an independent causal risk factor for atherosclerotic cardiovascular disease, and a landmark 30-year Women's Health Study found that elevated Lp(a), combined with high LDL and CRP, strongly predicted cardiovascular events over three decades.

Lp(a) concentration is predominantly determined by the LPA gene. Diet, exercise, and most lipid-lowering medications have minimal effect on Lp(a) levels — a person with optimal lifestyle habits can still carry significantly elevated Lp(a). This article is therefore about risk context and what the surrounding risk profile can and cannot change, not about lowering Lp(a) itself. The European Atherosclerosis Society (EAS) classifies Lp(a) above 50 mg/dL (approximately 125 nmol/L) as high risk — note that mg/dL and nmol/L are not interchangeable.

Because Lp(a) contributes to cardiovascular risk silently — promoting atherosclerosis over years or decades before any symptoms appear — symptoms reflect the consequences of cardiovascular disease rather than Lp(a) elevation directly. Testing is the only way to identify elevated Lp(a) before a cardiovascular event occurs.

Why Lp(a) is largely fixed across a lifetime

LPA genetic variation — the primary determinant

Evidence: Strong. More than 80% of the variation in Lp(a) concentration between individuals is attributable to variation in the LPA gene, and elevated Lp(a) clusters strongly within families. Because the level is genetically set early in life and remains stable, the EAS recommends that every adult be tested at least once — a single measurement provides useful lifetime risk context. Repeat testing is generally not informative unless a novel Lp(a)-specific therapy is initiated.

Premature cardiovascular disease and family history

Evidence: Strong. One of the strongest clinical associations with elevated Lp(a) is cardiovascular disease occurring earlier than expected, particularly in individuals who otherwise appear to have a favorable risk profile. People who experience a heart attack before age 55 (men) or 65 (women) with normal LDL cholesterol and no conventional risk factors are frequently found to have elevated Lp(a) when tested. A multi-ethnic prospective cohort published in the Journal of the American College of Cardiology (2024) confirmed that Lp(a) independently predicts long-term cardiovascular events across diverse populations. Because Lp(a) levels are predominantly genetic, a first-degree relative who experienced a heart attack or stroke before age 60 — particularly without conventional risk factors — increases the probability that elevated Lp(a) is contributing to familial cardiovascular risk.

Aortic valve calcification

Evidence: Strong. Elevated Lp(a) is specifically associated with calcific aortic valve disease, a condition where calcium deposits narrow the aortic valve opening and restrict blood flow from the heart. This association is stronger for Lp(a) than for LDL or standard lipid markers, with the mechanism thought to involve oxidized phospholipids carried on the Lp(a) particle. Symptoms of aortic valve stenosis — chest pain, shortness of breath, dizziness on exertion — may be the first clinical indication of elevated Lp(a) in some individuals, though the valve disease develops over many years before producing symptoms.

Lipid co-factors that amplify Lp(a) risk

Evidence: Strong. Lp(a) risk is additive with LDL: the two markers together are more hazardous than either alone. The 30-year Women's Health Study demonstrated that hs-CRP, LDL, and Lp(a) in combination predicted 30-year cardiovascular outcomes more powerfully than any single marker. Elevated Lp(a) is also associated with increased risk of ischemic stroke and peripheral arterial disease, reflecting generalized atherosclerosis that Lp(a) contributes to alongside other cardiovascular risk factors. Reducing the modifiable co-factors — LDL, blood pressure, and inflammation — is the primary lever available when Lp(a) itself cannot be changed.

Evidence-graded approaches to managing total risk with elevated Lp(a)

Lp(a) is largely genetically determined and does not respond meaningfully to lifestyle modification or most lipid-lowering medications. The following steps address the modifiable risk factors that amplify Lp(a)'s cardiovascular contribution.

1. LDL and ApoB reduction through diet, lifestyle, and (where indicated) statin or PCSK9 inhibitor therapy — Evidence: Strong. Lp(a) risk is amplified by concurrent LDL elevation; reducing LDL is the primary modifiable lever available. PCSK9 inhibitors also modestly reduce Lp(a) per FOURIER trial data, and this reduction contributes to reduced cardiovascular events. Precondition: elevated LDL or ApoB alongside elevated Lp(a). Retest: LDL + ApoB + Lp(a) at 12 weeks if initiating PCSK9 inhibitor therapy. Note: statin and PCSK9 inhibitor decisions are clinical; a provider determines the indication.

2. Blood pressure management — Evidence: Strong. Hypertension amplifies the atherogenic effect of elevated Lp(a); blood pressure control reduces cardiovascular event rate independent of lipid management. Precondition: blood pressure above 130/80 mmHg. Retest: blood pressure monitoring and lipid panel at 12 weeks.

3. Inflammation reduction through hs-CRP monitoring and lifestyle drivers — Evidence: Moderate. hs-CRP independently predicts cardiovascular events on top of Lp(a) per the Women's Health Study, and lifestyle-associated reductions in hs-CRP are achievable. Precondition: hs-CRP persistently above 1 mg/L. Retest: hs-CRP at 12 weeks.

4. Novel Lp(a)-specific RNA therapies if and when clinically available — Evidence: Limited. RNA-based therapies targeting Lp(a) specifically are currently in late-stage clinical trials and are not standard of care. This is a clinical trial or specialist consideration, not a self-directed step. Retest: Lp(a) at 12 weeks if enrolled in a therapy or trial.

Common missteps when interpreting an elevated Lp(a)

• Expecting diet and exercise to lower Lp(a) meaningfully. Unlike LDL, Lp(a) does not respond to dietary fat restriction, fiber, or exercise. Assuming lifestyle changes will bring it down leads to misplaced confidence and delayed management of the risk factors that are actually modifiable.
• Ignoring Lp(a) because "my LDL is fine." Lp(a) is an independent risk factor, separate from LDL. Normal LDL with elevated Lp(a) still carries elevated cardiovascular risk. The two markers are additive, not substitutable.
• Using mg/dL and nmol/L values interchangeably. The same numerical value in mg/dL and nmol/L carries very different clinical meaning. A result of 50 mg/dL is high risk; 50 nmol/L is not the same threshold. Confirm the units on any reported result before comparing to reference ranges.
• Assuming elevated Lp(a) is only a concern if cardiovascular symptoms are present. High Lp(a) produces no symptoms until cardiovascular disease has already developed. Testing in at-risk individuals — those with a family history of premature heart disease or unexplained cardiovascular events — is specifically motivated by this silence.

Routine vs urgent thresholds on an Lp(a) result

Elevated Lp(a) above 50 mg/dL (approximately 125 nmol/L) without symptoms, no family history of premature cardiovascular disease, and no concurrent cardiovascular findings is a routine primary care matter: document the result, manage the surrounding risk profile (LDL, blood pressure, inflammation), and discuss statin or PCSK9 inhibitor indication with a provider. Cardiologist evaluation is warranted when elevated Lp(a) appears alongside a cardiovascular event at an atypically young age, rapidly progressive aortic stenosis, or a family history of premature cardiovascular death — in these settings, specialist risk stratification and potential consideration for novel therapy trials is appropriate. There is an approximately linear relationship between Lp(a) concentration and cardiovascular risk across the full distribution, with prospective cohort data confirming that risk increases progressively with concentration and no clear threshold below which Lp(a) contributes no additional risk.

Why a single Lp(a) measurement usually suffices

Because Lp(a) is approximately 80–90% genetically determined, the level is unlikely to change meaningfully on repeat testing in the absence of a novel Lp(a)-specific agent. A single measurement provides useful lifetime risk context. Retesting is appropriate in two circumstances: once to confirm an initial value, and again if a PCSK9 inhibitor or novel RNA therapy is initiated. Routine annual retesting is not required unless therapy changes. When retesting, use fasted conditions, the same laboratory, and the same assay format to ensure comparability.

For monitoring the surrounding risk profile — the modifiable co-factors that amplify Lp(a) risk — the following companion markers are relevant:

• Lipoprotein(a) — Primary biomarker page for Lp(a) with reference ranges, unit clarification, and cardiovascular risk context
• ApoB — Total atherogenic particle count; Lp(a) is one particle contributing to total ApoB, and risk is additive
• hs-CRP — The 30-year Women's Health Study demonstrated that hs-CRP, LDL, and Lp(a) in combination predicted 30-year cardiovascular outcomes; hs-CRP adds independent risk on top of Lp(a)
• LDL cholesterol — Primary co-amplifier of Lp(a) risk; Lp(a) and LDL together are more hazardous than either alone
• Lipoprotein fractionation — Particle sizing provides additional risk stratification context on top of Lp(a)

When elevated Lp(a) belongs with a cardiologist

Lp(a) testing is particularly relevant if you have a family history of premature heart disease, have experienced a cardiovascular event despite normal LDL cholesterol, or have been told you have aortic valve disease. The EAS recommends that every adult have Lp(a) tested at least once. Elevated Lp(a) in the absence of other risk factors is a primary care conversation about managing the surrounding risk profile. When elevated Lp(a) coincides with a cardiovascular event at a young age, rapidly progressive aortic valve disease, or a strong family history of premature cardiovascular death, a cardiology referral is appropriate for specialist risk stratification and potential access to novel therapy trials.

Superpower's approach to cardiovascular risk — outlined at superpower.com/manifesto — is built around identifying silent risk factors like Lp(a) before they produce consequences. If your result warrants it, the clearest next step is a cardiology consult for elevated Lp(a) alongside a cardiovascular event at a young age or rapidly progressive aortic valve disease.